---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-000711"
form_type: "8-K"
ticker: "INSM"
cik: "0001104506"
company_name: "INSMED Inc"
filed_at: "2025-01-10T23:59:59+00:00"
generated_at: "2026-05-28T04:29:19.753083+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Insmed reports preliminary 2024 ARIKAYCE revenue of $363.7M, sets 2025 guidance of $405-425M

## Summary
- Preliminary 2024 ARIKAYCE global net sales of $363.7M, up 19% YoY; 2025 guidance $405-425M (11-17% growth)
- Brensocatib NDA for bronchiectasis submitted to FDA in Dec 2024; U.S. launch expected Q3 2025 under priority review
- Phase 2 TPIP in PAH fully enrolled (102 patients); topline data now expected mid-2025
- ENCORE trial for ARIKAYCE in MAC lung disease enrolled 425 patients (exceeding 400 target); topline Q1 2026
- IND cleared for DMD gene therapy INS1201; first patient dosing anticipated H1 2025

## SEC filing metadata
- accession: 0001140361-25-000711
- form_type: 8-K
- ticker: INSM
- cik: 0001104506
- company_name: INSMED Inc
- filed_at: 2025-01-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1104506/000114036125000711/0001140361-25-000711-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1104506/000114036125000711/ef20041296_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-000711
- JSON: https://secwatch.observer/filing/0001140361-25-000711.json
- Plain text: https://secwatch.observer/filing/0001140361-25-000711.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.